Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer-Reference-Cited by-同舟云学术

Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer

Published:2021-03-08 Issue:3 Volume:21 Page:441-448
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Cheng Li-Jen¹^ORCID,Wong Grace¹,Chay Wen-Yee²³,Ngeow Joanne²³⁴,Tan Yongqiang¹,Soon Swee Sung¹,Aziz Mohamed Ismail Abdul¹^ORCID,Pearce Fiona¹,Ng Kwong¹

Affiliation:

1. Agency for Care Effectiveness, Ministry of Health, Singapore

2. Division of Medical Oncology, National Cancer Centre Singapore, Singapore

3. Duke-NUS Medical School, National University of Singapore, Singapore

4. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1890587

Reference40 articles.

1. Singapore Cancer Registry, National registry of diseases office. Singapore cancer registry 50th anniversary monograph (1968-2017). Available from: https://www.nrdo.gov.sg/publications/cancer

2. Ovarian cancer statistics, 2018

3. Latest research and treatment of advanced-stage epithelial ovarian cancer

4. Ovarian cancer

5. US Food and Drug Administration. Lynparza tablet prescribing information; [cited 2020 Sep 22]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore;Expert Review of Pharmacoeconomics & Outcomes Research;2023-12-27

2. Multi-dimensional dynamic spatio-temporal evolution of the green development efficiency of water-energy-food in China;Water Policy;2023-02-01

3. Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China;Frontiers in Pharmacology;2023-01-04

4. Cost-effectiveness of PARP inhibitors in malignancies: A systematic review;PLOS ONE;2022-12-15

5. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china;Frontiers in Pharmacology;2022-08-12